Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanostart-Held Lumiphore Signs Cooperation Agreement with Oncology Company

Abstract:
Lumiphore Inc., a portfolio company of Nanostart AG, has signed a global cooperation with Algeta ASA, a company specializing in radiopharmaceutical therapies to treat cancer patients.

Nanostart-Held Lumiphore Signs Cooperation Agreement with Oncology Company

Frankfurt | Posted on October 31st, 2010

The agreement enables the integration of Lumiphore's Lumi4 complexes into the targeted radiotherapeutics and companion diagnostics from Algeta, according to the Company.
The highly targeted form of radiotherapy works by using a new class of radiation-emitting pharmaceuticals, called "alpha-pharmaceuticals". These act through molecular binding to cancer cells, where they can then emit alpha particles in precisely the right location to treat the tumor.

The Company said the agreement provides Algeta with an option to the exclusive rights to incorporate the Lumi4 isophthalamide chelation technology from Lumiphore into these targeted radiopharmaceutical therapeutics for cancer.

The Lumi4 complex functions by binding to a radioactive metal ion, which is the radiation source that emits the alpha particles which in turn destroy the tumor. At the same time, another portion of the complex binds to the pharmaceutical substance which is required to identify the tumor cells.

Under the terms of the agreement, Algeta obtains an exclusive 12-month option to an exclusive license for the use of Lumiphore's Lumi4 chelator technology within the field of therapeutic radiopharmaceuticals. The license will also give Algeta the right to use this technology in companion diagnostics, which are radiopharmaceuticals for determining either the suitability of patients for treatment and/or the effectiveness of treatment. Algeta will pay Lumiphore a fee on signing the option agreement and will make further payments should it exercise the option and take up the license.

"Lumiphore's goal is to bring the benefits of bifunctional metal-chelation technology to therapeutic markets that use targeted radiopharmaceuticals to treat cancer. The ability to chelate radioactive metal isotopes and covalently attach them to therapeutic antibodies, peptides, proteins, or other receptor targeting molecules will benefit targeted delivery to cancer sites and has the potential to make current therapeutic antibodies more effective," said Dr. Ken Raymond, President and CEO of Lumiphore.

"Using Lumi4 bifunctional chelates could create a new class of radioimmunotherapeutics," explained Thomas Ramdahl, Chief Technology Officer of Algeta. "By linking thorium-227 to selected tumor targeting antibodies using existing non-proprietary chelates, Algeta has already demonstrated in vivo the potential of its proprietary technology for enhancing the performance of radio-immunotherapies based on existing clinical antibodies. We believe that the new chelators will provide even better results."

####

For more information, please click here

Copyright © Nanostart AG,

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Tiny nanoclusters could solve big problems for lithium-ion batteries February 21st, 2017

Strem Chemicals and Dotz Nano Ltd. Sign Distribution Agreement for Graphene Quantum Dots Collaboration February 21st, 2017

Nominations Invited for $250,000 Kabiller Prize in Nanoscience: Major international prize recognizes a visionary nanotechnology researcher February 20th, 2017

Breakthrough with a chain of gold atoms: In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport February 20th, 2017

Nanomedicine

Nominations Invited for $250,000 Kabiller Prize in Nanoscience: Major international prize recognizes a visionary nanotechnology researcher February 20th, 2017

Good vibrations help reveal molecular details: Rice University scientists combine disciplines to pinpoint small structures in unlabeled molecules February 15th, 2017

In-cell molecular sieve from protein crystal February 14th, 2017

Cedars-Sinai, UCLA Scientists Use New ‘Blood Biopsies’ With Experimental Device to Speed Cancer Diagnosis and Predict Disease Spread: Leading-Edge Research Is Part of National Cancer Moonshot Initiative February 13th, 2017

Announcements

Tiny nanoclusters could solve big problems for lithium-ion batteries February 21st, 2017

Strem Chemicals and Dotz Nano Ltd. Sign Distribution Agreement for Graphene Quantum Dots Collaboration February 21st, 2017

Oxford Instruments announces Dr Brad Ramshaw of Cornell University, as winner of the 2017 Lee Osheroff Richardson Science Prize February 20th, 2017

Breakthrough with a chain of gold atoms: In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport February 20th, 2017

Nanobiotechnology

Good vibrations help reveal molecular details: Rice University scientists combine disciplines to pinpoint small structures in unlabeled molecules February 15th, 2017

In-cell molecular sieve from protein crystal February 14th, 2017

Cedars-Sinai, UCLA Scientists Use New ‘Blood Biopsies’ With Experimental Device to Speed Cancer Diagnosis and Predict Disease Spread: Leading-Edge Research Is Part of National Cancer Moonshot Initiative February 13th, 2017

Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer: Oncology industry veteran to oversee operations and product commercialization February 8th, 2017

Alliances/Trade associations/Partnerships/Distributorships

Strem Chemicals and Dotz Nano Ltd. Sign Distribution Agreement for Graphene Quantum Dots Collaboration February 21st, 2017

Leti Coordinating Project to Adapt Obstacle-Detection Technology Used in Autonomous Cars for Portable and Wearable Systems: INSPEX to Combine Knowhow of Nine European Organizations to Create Portable and Wearable Spatial-Exploration Systems February 2nd, 2017

GLOBALFOUNDRIES Expands Partner Program to Speed Time-to-Market of FDX™ Solutions: Increased support affirms FDXcelerator™ Program’s vital role in promoting broader deployment of GLOBALFOUNDRIES’ FDX™ portfolio December 15th, 2016

Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project